Fig 5 - by Melissa A. Hill (13170105)

Mice exposed to neonatal hyperoxia have persistent RVH and decreased vessel density at 21d. by Marta Perez (526067)

The result of the deviation of the angle axis between the RD and the three-dimensional point cloud coordinates during the actual movement process. by Hongliang Zou (20707270)

Subjects:

Metformin pre-administration decreases the oxidative stress, retains antioxidant effect and decreases apoptosis in colon and lung tissues in mice irradiated with GCRsim. by Silvia Siteni (10344070)

Decreases in CAPs. by Enrico Amico (527269)

“…<p>This figure shows the local decreases in co-activation from wakefulness to unconsciousness, using the same t-contrast as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100012#pone.0100012-Boveroux1" target="_blank">[7]</a>. …”

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on bacterial load after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on inflammatory mediators after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

Participants demographics at baseline. by Dawn M. Sears (4807302)

“…</p><p>Results</p><p>Participants in WLiM had decreased frequency of high emotional exhaustion (mean 2.9 decreased to 2.5), decreased occurrence of high depersonalization (mean 1.6 decreased to 1.3), and improved levels of personal accomplishment (mean 4.7 improved to 5.1) and leadership aspiration (mean 7.4 to 7.8). …”

The blood plasma, kidney, and brain concentration levels (ng/ml) of GSK360A presented for 5 and 24 hours after GSK360A (30 mg/kg) was administered orally by gavage. by Jin Zhou (90734)

Phenethyl isothiocyanate activates leptin signaling and decreases food intake by Miho Yagi (5921252)

“…Leptin is a weight-reducing hormone produced by adipose tissue, which decreases food intake <i>via</i> hypothalamic leptin receptors (Ob-Rb) and the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. …”

Interactions between E1A and PKA are required for full HAdV-5 progeny production. by Cason R. King (2633092)

“…Growth of WT virus was decreased by knockdown of each PKA subunit. Growth of HAdV E1A Δ4–25 was not affected by knockdown of PKA regulatory subunits, but was affected by knockdown of PKA Cα (though to a lesser extent than WT HAdV-5). …”

List of Included studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

KRAP−/− Mice Showed Decreased Weight-Gain and Decreased Adiposity. by Takahiro Fujimoto (268158)

Specific inhibition of ATG5 and ATG7 decrease low glucose-induced LC3-II accumulation. by Delphine Balmer (458897)

“…<p>Lentiviruses expressing specific shRNA were used to decrease the expression of ATG5 and ATG7 as described in material & methods, then each clonal cell colony was treated and cultured as mentioned in material & methods. …”

A non-significant decrease in time to peak desaturation was found post training; P = 0.07, ES = 0.53 ± 0.46. by Ben Jones (554472)

Structurally distinct inhibitors of Chk1 decrease Chk1 nuclear fluorescence following heating in a low well volume. by Andrew J. Massey (239469)

HIV-1 CA mutations selected during passage in rhTRIM5α-expressing cells decrease sensitivity to rhTRIM5α. by Steven J. Soll (270043)